Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Contraception and Contraceptive Drugs

  Free Subscription


Articles published in Gynecol Endocrinol

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    August 2022
  1. MIAO J, Lu J, Tang J, Lu P, et al
    Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
    Gynecol Endocrinol. 2022;38:656-660.
    PubMed     Abstract available


  2. MIN M, Ruan X, Wang H, Cheng J, et al
    Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients.
    Gynecol Endocrinol. 2022;38:676-680.
    PubMed     Abstract available


    July 2022
  3. GU M, Ruan X, Li Y, Li T, et al
    Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.
    Gynecol Endocrinol. 2022;38:598-602.
    PubMed     Abstract available


    June 2022
  4. OKYAY RE, Cetintas B, Akdoner A, Oztura I, et al
    The effect of oral contraceptive use on sympatic nerve activity in patients with polycystic ovary syndrome.
    Gynecol Endocrinol. 2022 Jun 7:1-6. doi: 10.1080/09513590.2022.2082403.
    PubMed     Abstract available


    May 2022
  5. LEPPANEN R, Tinkanen H, Huhtala H, Ahinko K, et al
    Single-administered GnRH agonist as luteal phase support in insemination cycles: a randomized controlled trial.
    Gynecol Endocrinol. 2022;38:438-442.
    PubMed     Abstract available


    April 2022
  6. REGIDOR PA, Palacios S, Colli E
    Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg.
    Gynecol Endocrinol. 2022;38:333-338.
    PubMed     Abstract available


    March 2022
  7. KIZILKAYA Y, Ibanoglu MC, Kiykac Altinbas S, Engin-Ustun Y, et al
    A prospective study examining the effect of dienogest treatment on endometrioma size and symptoms.
    Gynecol Endocrinol. 2022 Mar 23:1-4. doi: 10.1080/09513590.2022.2053956.
    PubMed     Abstract available


  8. VANNUCCINI S, Biagiotti C, Esposto MC, La Torre F, et al
    Long-term treatment of endometriosis-related pain among women seeking hormonal contraception.
    Gynecol Endocrinol. 2022 Mar 3:1-5. doi: 10.1080/09513590.2022.2047172.
    PubMed     Abstract available


    January 2022
  9. TRIGO ACM, Maron CC, Pinheiro MSA, da Silva SBL, et al
    Female sexual function in women using LARC methods.
    Gynecol Endocrinol. 2022;38:68-72.
    PubMed     Abstract available


    December 2021
  10. BUGGIO L, Barbara G, Facchin F, Ghezzi L, et al
    The influence of hormonal contraception on depression and female sexuality: a narrative review of the literature.
    Gynecol Endocrinol. 2021 Dec 16:1-9. doi: 10.1080/09513590.2021.2016693.
    PubMed     Abstract available


    November 2021
  11. JI M, Yuan M, Jiao X, Li Q, et al
    A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
    Gynecol Endocrinol. 2021 Nov 9:1-6. doi: 10.1080/09513590.2021.2000961.
    PubMed     Abstract available


    September 2021
  12. FERREIRA-FILHO ES, Bahamondes L, Duarte DC, Guimaraes ALM, et al
    Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
    Gynecol Endocrinol. 2021 Sep 6:1-4. doi: 10.1080/09513590.2021.1974380.
    PubMed     Abstract available


    August 2021
  13. REGIDOR PA, Colli E, Palacios S
    Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel.
    Gynecol Endocrinol. 2021 Aug 17:1-7. doi: 10.1080/09513590.2021.1963432.
    PubMed     Abstract available


  14. NIE L, Zou H, Ma X, Cheng L, et al
    A clinical observational study on the efficacy of subcutaneous etonogestrel implants for adenomyosis in 20 patients.
    Gynecol Endocrinol. 2021;37:735-739.
    PubMed     Abstract available


    June 2021
  15. YAO W, Dong X, Yu X, Luo J, et al
    The use of oral contraceptive is inversely associated with the risk of type 2 diabetes mellitus among middle-aged women.
    Gynecol Endocrinol. 2021 Jun 1:1-6. doi: 10.1080/09513590.2021.1932802.
    PubMed     Abstract available


    May 2021
  16. NICOLAS I, Martinez-Zamora MA, Gracia M, Carrion A, et al
    Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
    Gynecol Endocrinol. 2021 May 28:1-5. doi: 10.1080/09513590.2021.1929152.
    PubMed     Abstract available


  17. CECCARONI M, Clarizia R, Liverani S, Donati A, et al
    Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial.
    Gynecol Endocrinol. 2021 May 26:1-4. doi: 10.1080/09513590.2021.1929151.
    PubMed     Abstract available


  18. LI J, Sun Y, Mo S, Wang S, et al
    Effects of oral contraceptive for different responder women before GnRH antagonists: a systematic review and meta-analysis.
    Gynecol Endocrinol. 2021 May 11:1-10. doi: 10.1080/09513590.2021.1918664.
    PubMed     Abstract available


    March 2021
  19. MARIANI LL, Novara L, Mancarella M, Fuso L, et al
    Estradiol/nomegestrol acetate as a first-line and rescue therapy for the treatment of ovarian and deep infiltrating endometriosis.
    Gynecol Endocrinol. 2021 Mar 22:1-4. doi: 10.1080/09513590.2021.1903420.
    PubMed     Abstract available


  20. PIACENTI I, Viscardi MF, Masciullo L, Sangiuliano C, et al
    Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice?
    Gynecol Endocrinol. 2021 Mar 2:1-5. doi: 10.1080/09513590.2021.1892632.
    PubMed     Abstract available


  21. TROIA L, Martone S, Morgante G, Luisi S, et al
    Management of perimenopause disorders: hormonal treatment.
    Gynecol Endocrinol. 2021;37:195-200.
    PubMed     Abstract available


    February 2021
  22. BUYUK GN, Oskovi-Kaplan ZA, Kansu-Celik H, Neselioglu S, et al
    Copper and levonorgestrel containing intrauterine devices: comparison of their effect on oxidative stress markers.
    Gynecol Endocrinol. 2021 Feb 17:1-4. doi: 10.1080/09513590.2021.1878132.
    PubMed     Abstract available


  23. CLEMENZA S, Vannuccini S, Capezzuoli T, Meleca CI, et al
    Is primary dysmenorrhea a precursor of future endometriosis development?
    Gynecol Endocrinol. 2021 Feb 11:1-7. doi: 10.1080/09513590.2021.1878134.
    PubMed     Abstract available


    January 2021
  24. ATAKUL T, Tayyar AT, Turan OD, Celik SY, et al
    An assessment of the protective effect of gonadotropin-releasing hormone agonist and antagonist on bleomycin-induced ovarian toxicity in rats.
    Gynecol Endocrinol. 2021;37:46-50.
    PubMed     Abstract available


    October 2020
  25. LI X, Zhang X, Cai J, Pang J, et al
    Granulosa cells apoptosis and follicular fluid hormones: comparison of progestin-primed ovarian stimulation versus GnRH antagonist protocols.
    Gynecol Endocrinol. 2020 Oct 23:1-5. doi: 10.1080/09513590.2020.1822802.
    PubMed     Abstract available


    June 2020
  26. STEFANIAK A, Domitrz J, Siewko K, Szelachowska M, et al
    Pituitary adenoma and apoplexy during GnRH agonist treatment for IVF - case report.
    Gynecol Endocrinol. 2020;36:561-563.
    PubMed     Abstract available


    May 2020
  27. DEL FORNO S, Degli Esposti E, Salucci P, Leonardi D, et al
    Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
    Gynecol Endocrinol. 2020;36:445-447.
    PubMed     Abstract available


    April 2020
  28. LASORELLA S, Porto R, Iezzi ML, Pistone C, et al
    Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study.
    Gynecol Endocrinol. 2020;36:338-340.
    PubMed     Abstract available


    February 2020
  29. VIGNALI M, Belloni GM, Pietropaolo G, Barbasetti Di Prun A, et al
    Effect of Dienogest therapy on the size of the endometrioma.
    Gynecol Endocrinol. 2020 Feb 16:1-5. doi: 10.1080/09513590.2020.1725965.
    PubMed     Abstract available


    December 2019
  30. PALAIA I, Del Negro V, Fracassi A, Schiavi M, et al
    Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
    Gynecol Endocrinol. 2019 Dec 26:1-2. doi: 10.1080/09513590.2019.1707795.
    PubMed     Abstract available


  31. XHOLLI A, Filip G, Previtera F, Cagnacci A, et al
    Modification of endometrioma size during hormone therapy containing dienogest.
    Gynecol Endocrinol. 2019 Dec 16:1-5. doi: 10.1080/09513590.2019.1703942.
    PubMed     Abstract available


    October 2019
  32. MATSUSHIMA T, Akira S, Yoneyama K, Takeshita T, et al
    Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
    Gynecol Endocrinol. 2019 Oct 29:1-4. doi: 10.1080/09513590.2019.1683818.
    PubMed     Abstract available


    August 2019
  33. PALAIA I, Bardhi E, Boccia SM, Pecorini F, et al
    Severe hemoperitoneum due to endometriosis in a non-pregnant woman under dienogest therapy: a case report.
    Gynecol Endocrinol. 2019 Aug 13:1-2. doi: 10.1080/09513590.2019.1653843.
    PubMed     Abstract available


  34. GIARRE G, Franchini M, Castellacci E, Malune ME, et al
    Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
    Gynecol Endocrinol. 2019 Aug 8:1-4. doi: 10.1080/09513590.2019.1648419.
    PubMed     Abstract available


    July 2019
  35. BISCIONE A, Barra V, Bellone E, Severi FM, et al
    Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis.
    Gynecol Endocrinol. 2019 Jul 22:1-6. doi: 10.1080/09513590.2019.1640202.
    PubMed     Abstract available


  36. ANGIONI S, Pontis A, Malune ME, Cela V, et al
    Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study.
    Gynecol Endocrinol. 2019 Jul 16:1-3. doi: 10.1080/09513590.2019.1640674.
    PubMed     Abstract available


  37. MUZII L, Galati G, Di Tucci C, Di Feliciantonio M, et al
    Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain.
    Gynecol Endocrinol. 2019 Jul 14:1-3. doi: 10.1080/09513590.2019.1640199.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Contraception and Contraceptive Drugs is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: